The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model
Identifieur interne : 000286 ( Main/Merge ); précédent : 000285; suivant : 000287The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model
Auteurs : Jan A. C. Hontelez [Pays-Bas, Afrique du Sud] ; Nico Nagelkerke [Pays-Bas, Émirats arabes unis, Canada] ; Till B Rnighausen [Afrique du Sud, États-Unis] ; Roel Bakker [Pays-Bas] ; Frank Tanser [Afrique du Sud] ; Marie-Louise Newell [Afrique du Sud] ; Mark N. Lurie [États-Unis] ; Rob Baltussen [Pays-Bas] ; Sake J. De Vlas [Pays-Bas]Source :
- Vaccine [ 0264-410X ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : Afrique du Sud.
- topic : Vaccin.
English descriptors
Abstract
Background: The only successful HIV vaccine trial to date is the RV144 trial of the ALVAC/AIDSVAX vaccine in Thailand, which showed an overall incidence reduction of 31%. Most cases were prevented in the first year, suggesting a rapidly waning efficacy. Here, we predict the population level impact and cost-effectiveness of practical implementation of such a vaccine in a setting of a generalised epidemic with high HIV prevalence and incidence. Methods: We used STDSIM, an established individual-based microsimulation model, tailored to a rural South African area with a well-functioning HIV treatment and care programme. We estimated the impact of a single round of mass vaccination for everybody aged 15-49, as well as 5-year and 2-year re-vaccination strategies for young adults (aged 15-29). We calculated proportion of new infections prevented, cost-effectiveness indicators, and budget impact estimates of combined ART and vaccination programmes. Results: A single round of mass vaccination with a RV144-like vaccine will have a limited impact, preventing only 9% or 5% of new infections after 10 years at 60% and 30% coverage levels, respectively. Revaccination strategies are highly cost-effective if vaccine prices can be kept below 150 US$/vaccine for 2-year revaccination strategies, and below 200 US$/vaccine for 5-year revaccination strategies. Net cost-savings through reduced need for HIV treatment and care occur when vaccine prices are kept below 75 US$/vaccine. These results are sensitive to alternative assumptions on the underlying sexual network, background prevention interventions, and individual's propensity and consistency to participate in the vaccination campaign. Discussion: A modestly effective vaccine can be a cost-effective intervention in highly endemic settings. To predict the impact of vaccination strategies in other endemic situations, sufficient knowledge of the underlying sexual network, prevention and treatment interventions, and individual propensity and consistency to participate, is key. These issues are all best addressed in an individual-based microsimulation model.
Links toward previous steps (curation, corpus...)
- to stream Pascal, to step Corpus: 000155
- to stream Pascal, to step Curation: 000155
- to stream Pascal, to step Checkpoint: 000117
Links to Exploration step
Pascal:11-0425697Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model</title><author><name sortKey="Hontelez, Jan A C" sort="Hontelez, Jan A C" uniqKey="Hontelez J" first="Jan A. C." last="Hontelez">Jan A. C. Hontelez</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Public Health, Erasmus MC, University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Primary and Community Care, Radboud University Nijmegen Medical Center</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Africa Centre for Health and Population Studies, University of KwaZulu-Natal</s1><s2>Mtubatuba</s2><s3>ZAF</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mtubatuba</wicri:noRegion></affiliation></author><author><name sortKey="Nagelkerke, Nico" sort="Nagelkerke, Nico" uniqKey="Nagelkerke N" first="Nico" last="Nagelkerke">Nico Nagelkerke</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Public Health, Erasmus MC, University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Community Medicine, United Arab Emirates University</s1><s2>Al Ain</s2><s3>ARE</s3><sZ>2 aut.</sZ></inist:fA14><country>Émirats arabes unis</country><wicri:noRegion>Al Ain</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Department of Medical Microbiology, University of Manitoba</s1><s2>Winnipeg</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName><orgName type="university">Université du Manitoba</orgName></affiliation></author><author><name sortKey="B Rnighausen, Till" sort="B Rnighausen, Till" uniqKey="B Rnighausen T" first="Till" last="B Rnighausen">Till B Rnighausen</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Africa Centre for Health and Population Studies, University of KwaZulu-Natal</s1><s2>Mtubatuba</s2><s3>ZAF</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mtubatuba</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Global Health and Population, Harvard School of Public Health</s1><s2>Boston</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Bakker, Roel" sort="Bakker, Roel" uniqKey="Bakker R" first="Roel" last="Bakker">Roel Bakker</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Public Health, Erasmus MC, University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Tanser, Frank" sort="Tanser, Frank" uniqKey="Tanser F" first="Frank" last="Tanser">Frank Tanser</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Africa Centre for Health and Population Studies, University of KwaZulu-Natal</s1><s2>Mtubatuba</s2><s3>ZAF</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mtubatuba</wicri:noRegion></affiliation></author><author><name sortKey="Newell, Marie Louise" sort="Newell, Marie Louise" uniqKey="Newell M" first="Marie-Louise" last="Newell">Marie-Louise Newell</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Africa Centre for Health and Population Studies, University of KwaZulu-Natal</s1><s2>Mtubatuba</s2><s3>ZAF</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mtubatuba</wicri:noRegion></affiliation></author><author><name sortKey="Lurie, Mark N" sort="Lurie, Mark N" uniqKey="Lurie M" first="Mark N." last="Lurie">Mark N. Lurie</name><affiliation wicri:level="4"><inist:fA14 i1="07"><s1>Department of Epidemiology and the International Health Institute, Warren Alpert Medical School, Brown University</s1><s2>Providence, RI</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Rhode Island</region><settlement type="city">Providence (Rhode Island)</settlement></placeName><orgName type="university">Université Brown</orgName></affiliation></author><author><name sortKey="Baltussen, Rob" sort="Baltussen, Rob" uniqKey="Baltussen R" first="Rob" last="Baltussen">Rob Baltussen</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Primary and Community Care, Radboud University Nijmegen Medical Center</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="De Vlas, Sake J" sort="De Vlas, Sake J" uniqKey="De Vlas S" first="Sake J." last="De Vlas">Sake J. De Vlas</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Public Health, Erasmus MC, University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0425697</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0425697 INIST</idno><idno type="RBID">Pascal:11-0425697</idno><idno type="wicri:Area/Pascal/Corpus">000155</idno><idno type="wicri:Area/Pascal/Curation">000155</idno><idno type="wicri:Area/Pascal/Checkpoint">000117</idno><idno type="wicri:explorRef" wicri:stream="Pascal" wicri:step="Checkpoint">000117</idno><idno type="wicri:doubleKey">0264-410X:2011:Hontelez J:the:potential:impact</idno><idno type="wicri:Area/Main/Merge">000286</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model</title><author><name sortKey="Hontelez, Jan A C" sort="Hontelez, Jan A C" uniqKey="Hontelez J" first="Jan A. C." last="Hontelez">Jan A. C. Hontelez</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Public Health, Erasmus MC, University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Primary and Community Care, Radboud University Nijmegen Medical Center</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Africa Centre for Health and Population Studies, University of KwaZulu-Natal</s1><s2>Mtubatuba</s2><s3>ZAF</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mtubatuba</wicri:noRegion></affiliation></author><author><name sortKey="Nagelkerke, Nico" sort="Nagelkerke, Nico" uniqKey="Nagelkerke N" first="Nico" last="Nagelkerke">Nico Nagelkerke</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Public Health, Erasmus MC, University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Community Medicine, United Arab Emirates University</s1><s2>Al Ain</s2><s3>ARE</s3><sZ>2 aut.</sZ></inist:fA14><country>Émirats arabes unis</country><wicri:noRegion>Al Ain</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Department of Medical Microbiology, University of Manitoba</s1><s2>Winnipeg</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName><orgName type="university">Université du Manitoba</orgName></affiliation></author><author><name sortKey="B Rnighausen, Till" sort="B Rnighausen, Till" uniqKey="B Rnighausen T" first="Till" last="B Rnighausen">Till B Rnighausen</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Africa Centre for Health and Population Studies, University of KwaZulu-Natal</s1><s2>Mtubatuba</s2><s3>ZAF</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mtubatuba</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Global Health and Population, Harvard School of Public Health</s1><s2>Boston</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Bakker, Roel" sort="Bakker, Roel" uniqKey="Bakker R" first="Roel" last="Bakker">Roel Bakker</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Public Health, Erasmus MC, University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Tanser, Frank" sort="Tanser, Frank" uniqKey="Tanser F" first="Frank" last="Tanser">Frank Tanser</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Africa Centre for Health and Population Studies, University of KwaZulu-Natal</s1><s2>Mtubatuba</s2><s3>ZAF</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mtubatuba</wicri:noRegion></affiliation></author><author><name sortKey="Newell, Marie Louise" sort="Newell, Marie Louise" uniqKey="Newell M" first="Marie-Louise" last="Newell">Marie-Louise Newell</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Africa Centre for Health and Population Studies, University of KwaZulu-Natal</s1><s2>Mtubatuba</s2><s3>ZAF</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mtubatuba</wicri:noRegion></affiliation></author><author><name sortKey="Lurie, Mark N" sort="Lurie, Mark N" uniqKey="Lurie M" first="Mark N." last="Lurie">Mark N. Lurie</name><affiliation wicri:level="4"><inist:fA14 i1="07"><s1>Department of Epidemiology and the International Health Institute, Warren Alpert Medical School, Brown University</s1><s2>Providence, RI</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Rhode Island</region><settlement type="city">Providence (Rhode Island)</settlement></placeName><orgName type="university">Université Brown</orgName></affiliation></author><author><name sortKey="Baltussen, Rob" sort="Baltussen, Rob" uniqKey="Baltussen R" first="Rob" last="Baltussen">Rob Baltussen</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Primary and Community Care, Radboud University Nijmegen Medical Center</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="De Vlas, Sake J" sort="De Vlas, Sake J" uniqKey="De Vlas S" first="Sake J." last="De Vlas">Sake J. De Vlas</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Public Health, Erasmus MC, University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human immunodeficiency virus</term><term>Mathematical model</term><term>South Africa</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Virus immunodéficience humaine</term><term>Vaccin</term><term>Afrique du Sud</term><term>Modèle mathématique</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Afrique du Sud</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: The only successful HIV vaccine trial to date is the RV144 trial of the ALVAC/AIDSVAX vaccine in Thailand, which showed an overall incidence reduction of 31%. Most cases were prevented in the first year, suggesting a rapidly waning efficacy. Here, we predict the population level impact and cost-effectiveness of practical implementation of such a vaccine in a setting of a generalised epidemic with high HIV prevalence and incidence. Methods: We used STDSIM, an established individual-based microsimulation model, tailored to a rural South African area with a well-functioning HIV treatment and care programme. We estimated the impact of a single round of mass vaccination for everybody aged 15-49, as well as 5-year and 2-year re-vaccination strategies for young adults (aged 15-29). We calculated proportion of new infections prevented, cost-effectiveness indicators, and budget impact estimates of combined ART and vaccination programmes. Results: A single round of mass vaccination with a RV144-like vaccine will have a limited impact, preventing only 9% or 5% of new infections after 10 years at 60% and 30% coverage levels, respectively. Revaccination strategies are highly cost-effective if vaccine prices can be kept below 150 US$/vaccine for 2-year revaccination strategies, and below 200 US$/vaccine for 5-year revaccination strategies. Net cost-savings through reduced need for HIV treatment and care occur when vaccine prices are kept below 75 US$/vaccine. These results are sensitive to alternative assumptions on the underlying sexual network, background prevention interventions, and individual's propensity and consistency to participate in the vaccination campaign. Discussion: A modestly effective vaccine can be a cost-effective intervention in highly endemic settings. To predict the impact of vaccination strategies in other endemic situations, sufficient knowledge of the underlying sexual network, prevention and treatment interventions, and individual propensity and consistency to participate, is key. These issues are all best addressed in an individual-based microsimulation model.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>Canada</li><li>Pays-Bas</li><li>Émirats arabes unis</li><li>États-Unis</li></country><region><li>Gueldre</li><li>Hollande-Méridionale</li><li>Manitoba</li><li>Massachusetts</li><li>Rhode Island</li></region><settlement><li>Boston</li><li>Nimègue</li><li>Providence (Rhode Island)</li><li>Rotterdam</li><li>Winnipeg</li></settlement><orgName><li>Université Brown</li><li>Université du Manitoba</li></orgName></list><tree><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Hontelez, Jan A C" sort="Hontelez, Jan A C" uniqKey="Hontelez J" first="Jan A. C." last="Hontelez">Jan A. C. Hontelez</name></region><name sortKey="Bakker, Roel" sort="Bakker, Roel" uniqKey="Bakker R" first="Roel" last="Bakker">Roel Bakker</name><name sortKey="Baltussen, Rob" sort="Baltussen, Rob" uniqKey="Baltussen R" first="Rob" last="Baltussen">Rob Baltussen</name><name sortKey="De Vlas, Sake J" sort="De Vlas, Sake J" uniqKey="De Vlas S" first="Sake J." last="De Vlas">Sake J. De Vlas</name><name sortKey="Hontelez, Jan A C" sort="Hontelez, Jan A C" uniqKey="Hontelez J" first="Jan A. C." last="Hontelez">Jan A. C. Hontelez</name><name sortKey="Nagelkerke, Nico" sort="Nagelkerke, Nico" uniqKey="Nagelkerke N" first="Nico" last="Nagelkerke">Nico Nagelkerke</name></country><country name="Afrique du Sud"><noRegion><name sortKey="Hontelez, Jan A C" sort="Hontelez, Jan A C" uniqKey="Hontelez J" first="Jan A. C." last="Hontelez">Jan A. C. Hontelez</name></noRegion><name sortKey="B Rnighausen, Till" sort="B Rnighausen, Till" uniqKey="B Rnighausen T" first="Till" last="B Rnighausen">Till B Rnighausen</name><name sortKey="Newell, Marie Louise" sort="Newell, Marie Louise" uniqKey="Newell M" first="Marie-Louise" last="Newell">Marie-Louise Newell</name><name sortKey="Tanser, Frank" sort="Tanser, Frank" uniqKey="Tanser F" first="Frank" last="Tanser">Frank Tanser</name></country><country name="Émirats arabes unis"><noRegion><name sortKey="Nagelkerke, Nico" sort="Nagelkerke, Nico" uniqKey="Nagelkerke N" first="Nico" last="Nagelkerke">Nico Nagelkerke</name></noRegion></country><country name="Canada"><region name="Manitoba"><name sortKey="Nagelkerke, Nico" sort="Nagelkerke, Nico" uniqKey="Nagelkerke N" first="Nico" last="Nagelkerke">Nico Nagelkerke</name></region></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="B Rnighausen, Till" sort="B Rnighausen, Till" uniqKey="B Rnighausen T" first="Till" last="B Rnighausen">Till B Rnighausen</name></region><name sortKey="Lurie, Mark N" sort="Lurie, Mark N" uniqKey="Lurie M" first="Mark N." last="Lurie">Mark N. Lurie</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=MicroSimulV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000286 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000286 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= MicroSimulV1
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:11-0425697
|texte= The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model
}}
| This area was generated with Dilib version V0.6.38. |  |